These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 4826493)
1. Therapeutic synergism. Mantal N Cancer Chemother Rep 2; 1974 Mar; 4(1):147-9. PubMed ID: 4826493 [No Abstract] [Full Text] [Related]
2. [Theoretical and experimental bases for the polychemotherapy of cancer]. Delobel J; Mawas C; Israel L Poumon Coeur; 1968; 24(1):5-8. PubMed ID: 5652207 [No Abstract] [Full Text] [Related]
3. Drug activity and therapeutic synergism in cancer treatment. Carter WH; Wampler GL; Stablein DM; Campbell ED Cancer Res; 1982 Aug; 42(8):2963-71. PubMed ID: 6807534 [TBL] [Abstract][Full Text] [Related]
4. An empirical cellular approach to the improvement of cancer chemotherapy. Bruce WR; Lin H Cancer Res; 1969 Dec; 29(12):2308-13. PubMed ID: 5369679 [No Abstract] [Full Text] [Related]
6. [Current aspects of drug therapy of cancer]. Vicente J Rev Clin Esp; 1970 Dec; 119(6):501-16. PubMed ID: 4928318 [No Abstract] [Full Text] [Related]
7. Collection and presentation of combination data. Mancher RR Cancer Chemother Rep 2; 1974 Mar; 4(1):167-80. PubMed ID: 4826496 [No Abstract] [Full Text] [Related]
8. Practices and pitfalls of mouse cancer models in drug discovery. Kung AL Adv Cancer Res; 2007; 96():191-212. PubMed ID: 17161681 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic activity of pretazettine on Lewis lung carcinoma. Furusawa E; Lockwood RH Proc West Pharmacol Soc; 1981; 24():45-7. PubMed ID: 7255485 [No Abstract] [Full Text] [Related]
10. Planning combined therapy--the interaction of experimental and clinical studies. Carter SK Cancer Chemother Rep 2; 1974 Mar; 4(1):3-11. PubMed ID: 4826498 [No Abstract] [Full Text] [Related]
11. [Effect of prodigiozan on the therapeutic effect and toxicity of some antitumor preparations]. Veksler IG Antibiotiki; 1968 Jan; 13(1):72-7. PubMed ID: 4969473 [No Abstract] [Full Text] [Related]
12. Modeling therapy resistance in genetically engineered mouse cancer models. Rottenberg S; Jonkers J Drug Resist Updat; 2008; 11(1-2):51-60. PubMed ID: 18165147 [TBL] [Abstract][Full Text] [Related]
13. [Polychemotherapy of tumors and therapeutic synergism]. Stukov AN Vopr Onkol; 1979; 25(9):91-6. PubMed ID: 483726 [No Abstract] [Full Text] [Related]
14. [Effect of prodigiozan and its combinations with cytostatic agents on experimental tumor growth]. Ermol'eva AV; Givental' NI; Pasternak NA; Ravich IV Antibiotiki; 1966 Aug; 11(8):675-82. PubMed ID: 4970092 [No Abstract] [Full Text] [Related]
15. [Some methods of raising the selectivity of action of antineoplastic drugs]. Sof'ina ZP; Lagova ND; Lesnaia NA; Babushkina NA Vestn Akad Med Nauk SSSR; 1984; (5):70-7. PubMed ID: 6741252 [No Abstract] [Full Text] [Related]
16. Use of mathematical models for the evaluation of two- and three-drug combination chemotherapy in murine tumor models. Fichtner I; Steinhoff G Cancer Treat Rep; 1983; 67(7-8):621-9. PubMed ID: 6871880 [TBL] [Abstract][Full Text] [Related]
17. Clinical concepts derived from animal chemotherapy studies. Goldin A; Schabel FM Cancer Treat Rep; 1981; 65 Suppl 3():11-9. PubMed ID: 7049366 [TBL] [Abstract][Full Text] [Related]
18. [Effect of serotonin on the antineoplastic activity and toxicity of sarcolysin and dopan]. Mal'tseva LF Farmakol Toksikol; 1966; 29(6):698-701. PubMed ID: 6000367 [No Abstract] [Full Text] [Related]
19. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia]. Lengfelder E; Schultheis B; Büchner T; Hehlmann R Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223 [No Abstract] [Full Text] [Related]
20. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. Curnis F; Sacchi A; Corti A J Clin Invest; 2002 Aug; 110(4):475-82. PubMed ID: 12189241 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]